From the Press
Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health
Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time.
Genetika+, Pioneer in Personalized Medicine for Psychiatry, Raises $10 Million in an Oversubscribed Series A
Proceeds to fund clinical trials and scale up in the U.S. market. New investment underscores the company’s promise to transform precision medicine and mental health.
A successful female entrepreneur, Talia Cohen Solal is an extremely driven, compassionate, and curious individual. As the CEO & Co-Founder of Genetika+, a biotech start-up specialized in developing new tools for personalized medicine in major depression, she is advancing treatment in a much-needed space. In this interview, she speaks on a range of topics – from a unique scientific approach to depression treatment, to her journey from academic to entrepreneur, from challenges faced in the industry, to her passion for entrepreneurship. Here are some excerpts from the interview.
Discover 5 Top Healthcare Startups tackling Depression
Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the healthcare sector. This time, you get to discover 5 hand-picked startups tackling depression and mental health.
Israeli biotech company Matricelf wins Calcalist’s StartUp+ competition
The company developed a platform for 3D printing of tissues and organs. Genetika+, which developed a personalized technology for digital health took second place; winners awarded monetary prizes and office space.